SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

September 2018 Autoimmune News

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis. Findings suggested a relationship between the addition of adalimumab at 6 months after methotrexate failure and improved outcomes. PubMed, Ann Rheum Dis, 08/03/2018. (Also see Treatments for Rheumatoid Arthritis and Immunosuppressants)

MicroRNA expression in the affected skin of adult patients with IgA vasculitis. A positive association between the severity of purpura and skin miRNA-223-3p expression was found and aberrantly expressed miRNAs could represent a biomarker in adult IgAV. PubMed, Clin Rheumatol, 08/06/2018. (Also see Vasculitis)

Comorbidity in psoriatic arthritis (PsA) and rheumatoid arthritis (RA). High rates of comorbidity were found and the prevalence of depression, cardiovascular risk factors and other comorbidities were higher in PsA than RA participants. PubMed, Intern Med J, 07/26/2018. (Also see Psoriasis and Psoriatic Arthritis and Rheumatoid Arthritis in Overlap)

Clinicopathological features of lung cancer (LC) in patients with rheumatoid arthritis (RA). Lower likelihood for receiving surgery, radiotherapy, chemotherapy and targeted therapy was reported for LC patients with RA. Journal of Thoracic Disease, 08/02/2018. (Also see Symptoms and Complications of Rheumatoid Arthritis and Cancer)

Advances in the early diagnosis and therapy of inclusion body myositis (IBM). Antibody testing and muscle imaging results may improve our ability to diagnose IBM and the availability of effective disease modifying treatments could soon become a reality. PubMed, Curr Opin Rheumatol, 07/31/2018. (Also see Myopathy and Myositis)

Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. IL-18 is highly expressed in muscle tissue in the context of inflammatory myopathies and based on its plausible effector functions could provide a novel therapeutic target in future. PubMed, Rheumatology (Oxford), 08/08/2018. (Also see Treatments for Dermatomyositis and Polymyositis and Interleukins)

Adipokine interactions promote the pathogenesis of systemic lupus erythematosus (SLE). Adipokines levels and associated clinical manifestations suggest involvement of adipokines in disease pathogenesis of SLE. PubMed, Cytokine, 2018 Aug 8;111:20-27. Also see Research on Systemic Lupus Erythematosus)

Progression of subclinical atherosclerosis in systemic lupus erythematosus (SLE) versus rheumatoid arthritis: the impact of low disease activity. Plaque progression is accelerated in SLE regardless of disease activity, and is associated with antiphospholipid antibodies and the Systemic Coronary Risk Evaluation. PubMed, Rheumatology (Oxford), 08/08/2018. (Also see Antibodies in Lupus)

Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors (TNFi): a look beyond the baseline tuberculosis screening protocol. ‘Early TB’ was exceeded by TB occurring after 1 year of TNFi treatment, thereby, suggesting that further TB prevention measures were required. PubMed, Clin Rheumatol, 2018 Sep;37(9):2391-2397. (Also see Extrapulmonary Tuberculosis and Biologic Agents)

Aberrant T cell subsets and cytokines expression profile in systemic lupus erythematosus (SLE). T cell subsets and levels of chemokines and cytokines in patients with SLE and their relationships between disease activity and organ involvement were assessed. PubMed, Clin Rheumatol, 2018 Sep;37(9):2405-2413. (Also see B Cells and T Cells and Causes of Lupus)

Go to Autoimmune News: August 2018

SCLERO.ORG was the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses from 1998 to 2021. It was a grassroots movement from the original Scleroderma from A to Z web site, which was founded by Shelley Ensz. We were a 501(c)(3) U.S.-based public charitable foundation. We closed this web site and our nonprofit agency in April 2021.

International Scleroderma Network (ISN)